GlassScriptPhysician profile
Malik S Ali
NPI 1124037437
$11,894.02
in general payments reported to CMS, 2019-2025
59 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $1,470 · 2021: $1,665 · 2022: $1,622 · 2023: $1,686 · 2024: $2,020 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,383.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,736.61 | 2019-2025 | Airsupra, Lokelma, Breztri |
| Abbvie INC. | $1,455.96 | 2020-2025 | Vraylar, Mavyret, Viberzi |
| Gilead Sciences, INC. | $1,037.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.33 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $611.29 | 2019-2025 | Xarelto, Invega Sustenna |
| Pfizer INC. | $442.07 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $427.15 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $346.89 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $309.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $307.95 | 2019-2025 | Gardasil 9, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $307.71 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $304.13 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Ironwood Pharmaceuticals, INC | $282.48 | 2019-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $263.25 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.19 | 2019-2023 | Trintellix |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malik Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.